{
  "guideline": {
    "id": "PA166129553",
    "name": "Annotation of FDA Label for belinostat and UGT1A1",
    "source": "FDA",
    "version": 38,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166129553",
    "relatedChemicals": [
      {
        "id": "PA165971474",
        "name": "belinostat",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA420",
        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
        "symbol": "UGT1A1"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312581",
      "name": "Recommendation Annotation PA166312581",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA165971474",
          "name": "belinostat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452217300,
        "html": "<p>&quot;Reduce the starting dose of Beleodaq [belinostat] to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "UGT1A1": {
          "*28": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Beleodaq (Belinostat), NDA206256, Spectrum Pharmaceuticals, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206256"
    }
  ],
  "version": "2024-02-29-20-19"
}